


## HIV UPDATES

MARCH 18, 2022



This page includes the latest East Bay HIV updates, which include practice-changing studies and developments. [Please click here to share feedback.](#)

GET TESTED

GET PROTECTED

GET TREATMENT

RAPID ART

COVID-19

ARCHIVES

SIGN UP FOR OUR NEWSLETTER

### Jump to:

- [General HIV updates](#)
- [Prevention & testing](#)
- [STDs](#)
- [Treatment & cure](#)
- [Community updates](#) | [events](#) | [latest resources](#)
- [East Bay COVID guide](#) (opens separate page)

## NEW HIV/STD STUDIES AND GUIDELINES

### GENERAL HIV UPDATES

Current lists of open **Bay Area HIV, hepatitis and COVID studies** at UCSF are posted [here](#).



**CROI 2022**, the conference on the latest updates on global HIV research, took place February 13-16. Below are a few key resources and highlights:

- [HIV.gov and NIH highlights on prevention, treatment and cure](#)
- [HIV.gov and NIH highlights on aging, cancer prevention and the future of HIV](#)
- [Clinical Care Options summaries and practice-changing highlights from CROI 2022](#) (requires free registration; offers free CME/CEU)
- [View and download the original study abstracts on the CROI 2022 website.](#)
- The March 2022 IAS-USA *Topics in Antiviral Medicine* issue includes CROI 2022 abstracts and is [available here](#) for free download.

#### HIV treatment and cure highlights from CROI 2022:

- **Third case of documented HIV cure was highlighted in the [IMPAACT study](#).** All three known HIV cure cases had blood cancers and needed chemotherapy, radiation and transplant for cancer treatment. This case is unique because it's the first woman of mixed race who received the treatment in the US (NYC), and got a cord blood transplant rather than an adult bone marrow or blood transplant. She has done clinically well, with no graft-versus-host-disease, unlike the other two cases who got bone marrow or adult stem cell transplants (Timothy Brown, treated in Berlin, and Adam Castillejo, treated in London). Her viral load remained undetectable 14 months after stopping ART, and she's been in remission from AML for 4+ years. This treatment has a 30% risk of death, so it's very risky not something that we can do for people who don't need it for another condition, like a blood cancer. However, it does bring up potential mechanisms that can be studied for potentially safer ways to pursue cure treatments.
- The [ANCHOR study](#) showed that screening and treatment for anal dysplasia reduced anal cancer incidence by 57% over a

**median of just over 2 years. This is a reminder to continue/strengthen anal pap screening and HRA referrals!** Some of you may know this SF-based study well, as you referred and/or participated in it. This study was stopped early because it quickly became clear that anal pap screening, HRA and treatment for HSIL (93% treated with electrocautery) was effective in preventing anal cancer. Over a median of 26 months, 30 anal cancers were detected, 9 in the treatment group and 21 in the observation group, for a 57% reduction. This will likely lead to guidelines updates recommending regular anal cancer screening with anal paps, HRA for dysplasia, and treatment (electrocautery or IRC) for HSIL.

#### HIV antiretroviral treatment (ART) studies:

- **The CAB-RPV ATLAS-2M study** found that injectable CAB-RPV given every 8 weeks was non-inferior to when it was given every 4 weeks over a period of 3 years with an >85% overall viral load suppression rate, leading to the FDA updated approval for giving it every 8 weeks.
- **The DTG-3TC TANGO switch study** found that in patients virally suppressed on a 3-drug regimen, switching to DTG+3TC was non-inferior at 96 weeks (almost 2 years) of follow-up.
- **Several ART studies in resource-limited settings** found that DTG-based regimens worked well in first, second and third-line regimens compared to NNRTI and PI-based regimens, and TDF did better than AZT in NNRTI treatment failure, even with K65R resistance mutations.
- **A US-based study on DTG (dolutegravir or Tivicay) in pregnancy** using a huge pregnancy data-set found that there was no increased rate of neural-tube defects associated with DTG use in the US, where folic acid is added to many food products containing grains (unlike in Botswana, where they saw more neural tube defects). The [IMPAACT group](#) also found that DTG was better than EFV for sustained viral load suppression in pregnancy and post-partum, as well as associated with less stunting in infant growth.
- **Studies on the new ART agents:**
  - **Islatravir (ISL) long-acting translocation inhibitor (NRTTI) studies** found that oral, long-acting injectable, treatment and PrEP versions were associated with lymphopenia (up to 30% reduction in CD4 counts) despite viral load suppression, so the FDA placed a clinical hold on these studies so the lymphopenia can be investigated.
  - **Lenacapravir (LEN) long-acting capsid inhibitor:**
    - The [CALIBRATE study](#) found that LEN given sub-cutaneously (SC) every 6 months along with daily oral ART had 85-90% viral load suppression after 1 year, similar to other first-line ART regimens.
    - The [CAPELLA study](#) found that for people with multi-drug resistant HIV (resistance to at least 2 classes of HIV ART), adding LEN to their regimen led to 94% viral load suppression among those with 2 other active drugs and 79% in those with one other active drug at the 2-year follow-up mark.
    - The FDA did not approve LEN for MDR HIV due to some issue with the glass vials it is stored in. The manufacturer is now addressing the glass vial problem and hopefully will re-submit for FDA approval for people with MDR HIV for whom there are few or no other treatment options.

---

#### More general HIV updates:

The Alameda County HIV Epidemiology and Surveillance Unit has released the new report "[HIV in Alameda County, 2018-2020](#)", and its [Executive Summary](#). The report and executive summary are available on the [ACPHD website here](#).

The **2021 virtual Ryan White HIV Clinical Conference** was held October 3-6, 2021. [Please click here](#) see our resource page for key takeaways and links to slides from the conference.



**Another study shows worse COVID-19 outcomes for people living with HIV.** People living with HIV in Spain with detectable HIV viral loads, chronic comorbidities, age over 75, and people of non-Spanish origin (e.g. migrants) had increased rates of severe outcomes from COVID-19. Earlier studies showed similar patterns and are summarized [here](#).

---

## HIV PREVENTION AND TESTING

**The FDA has finally authorized a condom for anal sex**, in addition to vaginal sex. While many of us have long advised people to use condoms for anal sex, the FDA finally has enough data to allow the [ONE Condom](#) to add anal sex to the product label, based on a [study](#) showing the failure rate, defined as slippage or breakage, to be less than 1% during anal sex.

**Injectable long-acting PrEP (cabotegravir) is now FDA-approved!** Cabotegravir PrEP (brand name: *Apretude*) is given as two initial injections administered one month apart, and then every two months thereafter. Health plans regulated by the California Department of Insurance are [required](#) to cover all PrEP drugs and related clinical services without cost sharing – including injectable PrEP. Processes for getting it covered are still getting worked out.

**The CDC released its updated PrEP Clinical Practice Guideline on December 10, 2021.** The update includes guidance for recommended initial

and follow-up STD screening, revised HIV testing strategies, and recommended primary care practices for patients being prescribed oral or injectable PrEP. The Clinical Providers Supplement includes revised checklists, patient information sheets, and billing codes for both oral and injectable PrEP and includes guidance for counseling patients about adherent PrEP use.

Key revisions to the guideline include (from Demetre C. Daskalakis, MD, MPH, Director of the CDC Division of HIV Prevention):

- A new recommendation for providers to inform all sexually active adults and adolescents about PrEP. This is intended to increase awareness of PrEP more broadly.
- A recommendation that, in addition to taking a very brief history to identify persons with indications for PrEP, providers prescribe PrEP to anyone who requests it, even if they do not report specific HIV risk behaviors. This recommendation is intended to make PrEP available to people who may be apprehensive about sharing potentially stigmatized HIV risk behaviors with their provider.
- A recommendation for F/TAF (Descovy) as an FDA-approved PrEP option for sexually active men and transgender women at risk of getting HIV, based on recent data showing its effectiveness for these populations.
- A new section on prescribing bimonthly intramuscular injections of cabotegravir (CAB) for sexually active men and women who could benefit from PrEP, pending FDA data review and potential regulatory action.

**A study of PrEP services at Kaiser Northern California** from 2012 to 2019 showed that among those linked to PrEP care, people less likely to receive PrEP prescriptions included young adults ages 18–25, people with substance use disorders, people living in lower income neighborhoods, women, and among African American and Latinx people.

**Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women:** A study of 4,566 people including 570 (12%) transgender women, participants were randomized to receive TDF-FTC vs. CAB LA for PrEP. The results showed that CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection. The study authors write that “strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure.”

---

## STD STUDIES AND GUIDELINES

**A resurgence in STD cases:** New [CDC data](#) show that during March–April 2020, reported STD cases dramatically decreased compared to the same time in 2019. However, a resurgence in gonorrhea and syphilis cases later in the year suggest overall STDs may have increased during 2020.

The CDC released their updated **2021 Sexually Transmitted Infections Treatment Guidelines**. Click on this [link](#) to access the full guidelines and visit their [provider resource page](#) for copies of a summary wall chart and pocket guide.

---

## HIV CARE, TREATMENT AND CURE

The HRSA [Ryan White HIV/AIDS Program Annual Client-Level Data Report 2020](#) was published December 2021. [Click here](#) for more HRSA HIV reports.

**An international collaborative group has released the first Global Cure Strategy**, which summarizes the priorities and recommendations for the next 5 years. The collaborative group included community members, scientific and industry experts. Key goals include understanding and measuring HIV reservoirs, identifying mechanisms of virus control, targeting the HIV provirus, developing ways to support immune control, cell and gene therapy, pediatric remission and cure, and the social, behavioral and ethical aspects of cure.

A [case report](#) has been published of a woman in Argentina who has undetectable HIV viral load after more than 8 years off ART, even with ultra-sensitive testing of multiple organs and reservoirs. It appears that **her immune system may have cleared the HIV-1 virus**, an extremely rare phenomenon.

The **San Francisco 2017–2018 HIV Medical Monitoring Project (MMP) Report** was released in July. Interview and medical record data from 361 participants were collected between June 2017 and May 2019 and features new data on long-term survivors and resiliency.

The CDC [published data](#) on August 5, 2021 from the 2019–2020 cycle of the **HIV National Medical Monitoring Project** (MMP). The MMP is an annual, cross-sectional survey that reports nationally representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV infection (PLWH) in the United States.

**Findings in this latest national MMP report** include:

- 79% of PLWH surveyed were retained in care
- 61% were virally suppressed
- 16% had symptoms of depression
- 21% had recent symptoms of anxiety
- 9% experienced homelessness
- The median HIV-related stigma score was 30.7 (0= lowest stigma and 100= highest stigma)

**A separate MMP report on PLWH in the US showed that 25% had experienced discrimination in health care settings.** People ages 18-29, transgender people, LGBTQ+ people and those who were experiencing homelessness or incarceration were significantly more likely to experience discrimination, and were more likely to have missed visits, not take ART or miss ART doses.

The authors conclude, "Interventions that address the sociocultural and structural factors associated with discrimination in all health care settings are needed to improve health outcomes among PWH and end the HIV epidemic in the United States."

## COMMUNITY BULLETIN BOARD

Updated March 3rd, 2022

### Job Opportunities:

- **Alameda Health Consortium/Community Health Center Network** is recruiting a new CEO! Find out more by [clicking here](#).
- **EBAC (East Bay AIDS Center/East Bay Advanced Care) Medical Group** is recruiting for a full time or near full-time HIV physician boarded in internal medicine, family medicine, and/or infectious diseases! The successful candidate will have their own outpatient panel of HIV primary care and prevention patients, and also provide consultation on the inpatient HIV service at Summit Hospital in Oakland, and Alta Bates Hospital in Berkeley. The full job description can be found at the [AAHIVM Career Center](#). Interested parties should email their CV to medical directors Dr. Jeff Burack (burackj@sutterhealth.org) and Dr. Michele Tang (patangm@sutterhealth.org).
- The **California Department of Public Health (CDPH), Sexually Transmitted Diseases Control Branch, Policy and Viral Hepatitis Prevention Section** is recruiting a Project Policy Analyst 4 Lead STD Policy Analyst position through the UCSF. For more information and to apply for the position, [please click here](#).
- The **Department of Ob/Gyn & Reproductive Sciences at UCSF** is hiring for a Vice Chair of Equity, Inclusion, and Structural Change. The Vice Chair will be part of a dyad partnership, collaborating to advance diversity, equity, and inclusion in the Department leading to a dynamic and inclusive environment that fulfills the missions of clinical care, service, research, education, and advocacy. To learn about the opportunity, [please click here](#).
- **ACPHD's Office of HIV Prevention** is recruiting for a Data-to-PrEP Program Specialist position with the Office of HIV Prevention. [Click here](#) for more information.



## PROGRAM SPECIALIST

Communicable Disease Control & Prevention

**Alameda County Public Health's  
Division of Communicable Disease  
Control & Prevention**  
is recruiting for a provisional  
**Data-to-PrEP Program Specialist.**

The Offices of HIV Care and Prevention's mission is: to reduce the rates of new HIV infections; increase the number of county residents who know their HIV status earlier through HIV testing; and linking individuals who are positive into care.

**DCDCP**

**\$74,401.60 - \$109,803.20 Annually**  
**Plus, excellent benefits!**

**\*Provisional Appointments:** For a *provisional appointment*, a civil service exam is not required; however, to obtain a regular position, the appointee will need to compete successfully in a County Exam when open.

Alameda County Health Care Services Agency is enriched with a diverse workforce. We believe the best way to deliver optimal programs and services to our communities is to hire and promote talents that are representative of the communities we serve. Diverse candidates are strongly encouraged to apply.

**HOW TO APPLY**  
An Alameda County Application is required to be considered for this recruitment.  
Please email the [County Application](#) and a cover letter to:  
Dawn Smith  
([Dawn.Smith@acphd.org](mailto:Dawn.Smith@acphd.org))

The application template is available online on Alameda County's On-Line Employment Center at:  
[www.iobaps.com/alameda](http://www.iobaps.com/alameda)

**NEW USERS** can click on "New User Registration" to fill out an application template. Once the application is completed, please click on the "Review" tab to "Print/Save My Application". A PDF version or digital scan of the application must be submitted to the email address above.

**OPEN UNTIL FILLED**

For clients:



**Join our research study to:**

Make a  
difference for  
people living  
with HIV

Earn up to  
**\$200**  
annually

Be part of the  
largest ongoing  
study that  
includes people  
with AND  
without HIV.

**TO JOIN:**

Email us at: [MWCCS@ucsf.edu](mailto:MWCCS@ucsf.edu)

San Francisco: (415) 502-8800

Oakland: (415) 476-2982

Text: (415) 770-1101



Phyllis Tien, MD, Principal Investigator  
IRB#: 21-33925

The **MWCCS** is an adult health study at UCSF that aims to address the effects of HIV infection on the physical, emotional, and social health of adults. To be eligible, individuals (all genders are included) need to be: Ages 30-70, HIV positive or negative, Speak English or Spanish. Eligible participants can earn up to \$200 annually. Interested individuals can email [mwccs@ucsf.edu](mailto:mwccs@ucsf.edu) or call 415-502-8800 for more information.

**IAPAC** is circulating a community Ending the HIV Epidemic Survey. The main purpose of this study is to learn how much influence people living with HIV believe they have in decisions regarding government initiatives. The research will also look at how those perceptions differ by race, gender, and age. This poll is directed specifically towards community stakeholders and can be done in either [English](#) or [Español](#).

**PrEPTECH** is a paid study to see if an online program will help people who aren't already on PrEP get and stay on it. PrEPTECH is currently looking for young (15-27) gay or bi men and trans women in California or Florida. Everyone who participates in the study will be compensated up to \$150. Learn more [here](#).



Dream Youth Clinic  
**WE ARE HIRING!!**  
**A YOUTH SOCIAL MEDIA INTERN!**

- ✓ Ages 13-24
- ✓ Social Media knowledgeable
- ✓ Passion for creating digital products

★ Paid Opportunity

**APPLY NOW**

Send Us Your Resume or ask questions!  
Dream@rootsclinic.org

ROOTS community health center



**Dream Youth Clinic** is hiring a Youth Dream Social Media Intern! This will be a part-time paid opportunity (\$20 the hour) for a person aged 13-24 who has experience navigating and creating digital products for social media (e.g. TikTok; Instagram live etc.) Resumes can be sent to [Dream@rootsclinic.org](mailto:Dream@rootsclinic.org)



**DREAM YOUTH CLINIC**

Are you pregnant, parenting or planning to become pregnant?

# Young Mother's Rising Virtual Group



**NEW TIME AND DAY!**


Join us on Zoom Wednesdays; 3:30-4:30pm

\$25 e-gift card will be provided to all participants!



**Dream Youth Clinic's Young Mothers Rising program** provides wrap-around support for young people who choose to parent, who

are pregnant or who plan to become pregnant. The program also serves as a protective space for pregnant and parenting youth affected by sex trafficking to support both individual and collective healing from sexual trauma. For more info reach out to [dream@rootsclinic.org](mailto:dream@rootsclinic.org)



**Dream Youth Clinic**  
583 Fifth St. A Oakland (Mon & Wed) 1-5pm  
200 Harrison St. Oakland (T, Th, Fri) 1-5pm

**COVID-19 VACCINES + COVID-19 TESTING FOR AGES 13-24**

**COVID-19 VACCINE**  
WE OFFER FREE DROP-IN COVID-19 VACCINES!

**COVID-19 TESTING**  
WE OFFER FREE DROP-IN COVID-19 RAPID AND LAB COVID-19 TESTING DURING CLINIC HOURS 1-5PM.  
COME IN EARLY FOR RAPID TESTING SERVICES!

Have questions about the COVID-19 vaccine? Come in and ask our medical staff!

Email: [dream@rootsclinic.org](mailto:dream@rootsclinic.org)  
Instagram: @dreamyouthclinic



**Dream Youth Clinic**  
Instagram: @dreamyouthclinic  
Email: [dream@rootsclinic.org](mailto:dream@rootsclinic.org)

**PROGRAMS OFFERED**

- The Garden of Dreams**  
YOUTH LED COMMUNITY GARDEN. PAID PLANTING, EDUCATIONAL WORKSHOPS + GARDEN VOLUNTEERING OPPORTUNITIES AVAILABLE! FOR YOUTH AGES 13-24!
- Cooking Workshops**  
YOUTH COOKING WORKSHOPS AT DREAMCATCHER USING VEGGIES FROM OUR GARDEN OF DREAMS FOR AGES 13-18!
- The Truth About Using**  
PAID YOUTH INTERNSHIPS TO PROVIDE PEER HEALTH EDUCATION AND CREATE MULTI-MEDIA RELATED TO DRUGS AND ALCOHOL! AGES 13-18
- Girlx Work!**  
CAREER GOALS AND SCHOLARSHIP SUPPORT FOR FEMALE-IDENTIFIED YOUTH AGES 13-24!
- Young Mothers Rising**  
TWICE A MONTH VIRTUAL GROUP FOR PREGNANT, PARENTING, OR PLANNING YOUNG MOTHERS WITH \$25 GIFT CARD + DIAPER + FOOD AND HEALTH NAVIGATION SUPPORT + MORE! AGES 13-24!

**Events:**

**Pacific AIDS Education and Training Center** and partners are hosting the upcoming virtual event via Zoom titled Ending the Silent Epidemics: Substance Use as a Driver for HIV. March 9 & March 10, 10 AM-2 PM. Register for [day one here](#) and [day 2 here](#).

## UPCOMING EVENTS

### CDPH ETE STATEWIDE TOWN HALL

📅 March 18 from 12:00 pm to 2:00 pm

### YOUTH ENGAGEMENT WORKING GROUP

📅 [Youth](#)


📅 March 28 from 2:00 pm to 3:30 pm

### WEBINAR: SAFETY OPTIMIZATION (HARM REDUCTION) FOR SEXUAL & GENDER DIVERSE PEOPLE WHO PARTICIPATE IN CHEMSEX (APRIL 1)

📅 [Harm Reduction](#), [Linkage and Retention](#), [Prevention](#), [Trainings](#)

📅 April 1 from 9:00 am to 10:00 am

## LATEST RESOURCES



US Public Health Service

### PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES – 2021 UPDATE

A CLINICAL PRACTICE GUIDELINE

## OMICRON AND VARIANT FAQs

MARCH 18, 2022

➤ [COVID](#), [Data](#), [Epidemiology](#), [Prevention](#)


[READ MORE](#)

## CDC PREP CLINICAL GUIDELINES 2021 UPDATE

MARCH 17, 2022

➤ [Clinical Guides](#), [PrEP](#), [Prevention](#)

[READ MORE](#)




## CROI 2022 HIGHLIGHTS AND RESOURCES

MARCH 15, 2022

➤ [Clinical Guides](#), [Data](#), [Epidemiology](#), [HIV treatment](#), [Research](#)

[READ MORE](#)

[← BACK TO UPDATES](#)



[ABOUT](#)  
[SERVICES](#)  
[HIV](#)  
[COVID-19](#)  
[RESOURCES](#)

[UPDATES](#)  
[EVENTS](#)  
[GET INVOLVED](#)  
[DONATE](#)



[Privacy Policy](#) [Site Map](#) [Site Credits](#) [Contact Us](#) [Login](#)